---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-020687"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:41:49.496616+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals reports Telomir-1 restores mitochondrial function without cell division in Progeria study

## Summary
- Telomir-1 increased mitochondrial energy (WST-1 assay) and reduced ROS under basal and stress conditions.
- No increase in live cell number was observed, confirming no stimulation of cell proliferation.
- Activity was greater in Progeria fibroblasts than in healthy cells, suggesting disease-selective effects.
- Results may inform development in Parkinson's, ALS, Alzheimer's, Werner's, and Progeria.
- IND-enabling studies for Telomir-1 are ongoing; clinical path evaluation continues.

## SEC filing metadata
- accession: 0001641172-25-020687
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225020687/0001641172-25-020687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225020687/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-020687
- JSON: https://secwatch.observer/filing/0001641172-25-020687.json
- Plain text: https://secwatch.observer/filing/0001641172-25-020687.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.